

# Autophagy in Immunity and Infection

*A Novel Immune Effector*

*Edited by*  
*Vojo Deretic*



WILEY-  
VCH

WILEY-VCH Verlag GmbH & Co. KGaA



**Autophagy in Immunity  
and Infection**

*Edited by  
Vojo Deretic*

## ***Related Titles***

Frosch, M., Maiden, M.C.J. (eds.)

### **Handbook of Meningococcal Disease** **Infection Biology, Vaccination, Clinical Management**

2006

ISBN 3-527-31260-9

Lutz, M. B., Romani, N., Steinkasserer, A. (eds.)

### **Handbook of Dendritic Cells** **Biology, Diseases and Therapies**

2006

ISBN 3-527-31109-2

Frelinger, J.A. (ed.)

### **Immunodominance** **The Choice of the Immune System**

2006

ISBN 3-527-31274-9

Pollard, K. M. (ed.)

### **Autoantibodies and Autoimmunity** **Molecular Mechanisms in Health and Disease**

2006

ISBN 3-527-31141-6

Kropshofer, H., Vogt, A. B. (eds.)

### **Antigen Presenting Cells** **From Mechanisms to Drug Development**

2006

ISBN 3-527-31108-4

Hamann, A., Engelhardt, B. (eds.)

### **Leukocyte Trafficking** **Molecular Mechanisms, Therapeutic Targets, and Methods**

2005

ISBN 3-527-31228-5

# Autophagy in Immunity and Infection

*A Novel Immune Effector*

*Edited by*  
*Vojo Deretic*



WILEY-  
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

#### The Editor

**Prof. Dr. Vojo Deretic**

Department of Molecular Genetics  
& Microbiology & Physiology  
University of New Mexico Health Sciences Center  
915 Camino de Salud, NE  
Albuquerque, NM 87131-001  
USA

■ All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

**Bibliographic information published by**

**Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <<http://dnb.ddb.de>>

© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**Composition** K+V Fotosatz GmbH, Beerfelden

**Printing** betz-druck GmbH, Darmstadt

**Bookbinding** Litges & Dopf Buchbinderei GmbH, Heppenheim

**Cover Design** Adam Design, Weinheim

**ISBN-13:** 978-3-527-31450-8

**ISBN-10:** 3-527-31450-4

## Contents

Preface *XII*

Foreword *XV*

List of Contributors *XIX*

Colour Plates *XXIII*

### Part I Introduction to Autophagy

#### 1 Overview of Autophagy 3

*Julie E. Legakis and Daniel J. Klionsky*

##### 1.1 Overview of Autophagy 3

##### 1.2 The Discovery of Autophagy 5

##### 1.3 Mechanistic Aspects of Autophagy 7

##### 1.3.1 Induction 9

##### 1.3.2 Cargo Selection and Packaging 10

##### 1.3.3 Vesicle Nucleation 11

##### 1.3.4 Vesicle Expansion and Completion 11

##### 1.3.5 Retrieval 12

##### 1.3.6 Targeting, Docking and Fusion of the Vesicle with the Lysosome/ Vacuole 12

##### 1.3.7 Breakdown of the Vesicle and its Cargo 12

##### 1.4 Autophagy and Immunity 13

References 14

#### 2 Cell Biology and Biochemistry of Autophagy 19

*Edmond Chan, Robert Köchl and Sharon A. Tooze*

##### 2.1 Introduction 19

##### 2.2 Autophagic Pathway 20

##### 2.2.1 Formation of Autophagosomes 20

##### 2.2.2 Fusion of AV with Endocytic Pathways and Maturation 22

2.2.3	Endosomes and Lysosomes	25
2.3	Regulation of Mammalian Autophagy by Amino Acids and Hormones	27
2.3.1	Amino Acids	28
2.3.2	Hormones	30
2.3.3	Longer-term Regulation	31
2.3.4	The Nutrient Sensor Target of Rapamycin (TOR)	32
2.3.5	Upstream of TOR	36
2.3.6	Downstream of TOR	38
2.4	Methods to Measure Autophagy	41
2.4.1	Microscopic Methods	42
2.4.1.1	Electron Microscopy	42
2.4.1.2	Light Microscopy	42
2.4.2	Biochemical Methods	45
2.4.2.1	Formation and Induction	45
2.4.2.2	Fusion	46
2.4.2.3	Purification of Autophagosomes from Rat Liver	47
2.4.2.4	Inhibition of Autophagy	47
2.4.2.5	Common Questions	48
2.4.3	Summary and Outlook	48
	References	49
<b>3</b>	<b>Transgenic Models of Autophagy</b>	<b>55</b>
	<i>Noboru Mizushima</i>	
3.1	Molecular Mechanism of Mammalian Autophagy	55
3.1.1	Atg12 Conjugation System	55
3.1.2	Atg8/Microtubule-associated Protein 1 Light Chain 3 (LC3) Conjugation System	56
3.1.3	Class III Phosphatidylinositol-3-kinase (PI3K) Complex	57
3.1.4	Atg1 Kinase Complex	57
3.1.5	Other Factors	58
3.2	Autophagy Indicator Mice: Green Fluorescent Protein (GFP)–LC3 Transgenic Mice	58
3.3	Mouse Models Deficient for Autophagy-related Genes	60
3.3.1	Atg5-deficient Mice	61
3.3.2	Atg7-deficient Mice	63
3.3.3	Beclin 1-deficient Mice	63
3.4	Concluding Remarks	64
	References	64
<b>4</b>	<b>Autophagy in Disease and Aging</b>	<b>69</b>
	<i>Marta Martinez-Vicente, Susmita Kaushik and Ana Maria Cuervo</i>	
4.1	Introduction	69
4.2	Autophagy in Neurodegenerative Disorders	70
4.2.1	Protein Misfolding and Aggregation	71



4.2.2	Parkinson's Disease	73
4.2.3	Alzheimer's Disease	75
4.2.4	Huntington's Disease	76
4.2.5	Prion Diseases	77
4.2.6	Niemann–Pick Type C	78
4.3	Autophagy and Cancer	79
4.3.1	Proteolysis of long-lived Proteins and Effect of Nutrient Deprivation in Cancer Cells	79
4.3.2	Autophagic Cell Death in Response to Anticancer Treatment	80
4.3.3	Molecular Mechanisms	82
4.3.3.1	Beclin 1	82
4.3.3.2	PI3K–Akt–mTOR Pathway	82
4.3.4	Possible Therapeutic Attempts	84
4.4	Myopathies	85
4.4.1	Danon Disease	85
4.4.2	XMEA	86
4.4.3	Rimmed Vacuolar Myopathies	86
4.4.4	Other Myopathies	87
4.4.5	Cardiomyopathies and Myocardial Cell Death	87
4.5	Liver Diseases	88
4.6	Diabetes Mellitus	89
4.7	Aging	90
4.7.1	Changes in Protein Degradation with Age	90
4.7.2	Age-related Changes in Autophagy	91
4.7.3	Consequences of the Failure of Autophagy in Aging	93
4.7.4	Slowing Down Aging?	94
4.8	Concluding Remarks and Pending Questions	94
	References	95

## **5 The Dual Roles for Autophagy in Cell Death and Survival 105**

*Yayanta Debnath and Christopher Fung*

5.1	Introduction	105
5.2	Types of Programmed Cell Death	106
5.2.1	Type 1 Programmed Cell Death	106
5.2.2	Type 2 Programmed Cell Death	106
5.2.3	Type 3 Programmed Cell Death	107
5.2.4	Other Types of Programmed Cell Death	107
5.3	The Contribution of Autophagy to Programmed Cell Death	108
5.3.1	Death Processes That Require <i>atg</i> Genes	108
5.4	The Combined Activation of Autophagy and Apoptosis during Programmed Cell Death	110
5.5	Emerging Relationships between Apoptosis and Autophagy	112
5.6	Autophagy and Cell Survival	113
5.6.1	Autophagy is Cytoprotective during Nutrient Depletion in Mammalian Cells	114

- 5.6.2 Autophagy and Neuroprotection 115
- 5.6.3 Cytoprotective Roles of Autophagy in the Response to Infectious Pathogens 116
- 5.7 Autophagy and Organism Survival 118
- 5.8 Concluding Remarks 119
- Acknowledgments 119
- References 120

## Part II Autophagy and Bacteria

- 6 Autophagy and *Mycobacterium tuberculosis* 129**  
*James Harris, Sergio De Haro and Vojo Deretic*
  - 6.1 Introduction 129
  - 6.2 *M. tuberculosis* Blocks Phagolysosome Biogenesis in Macrophages 130
  - 6.3 Autophagy and the Host Response to *M. tuberculosis* 131
  - 6.4 Regulation of Autophagy by the Immune System 133
  - 6.5 p47 GTPases and Autophagy 134
  - 6.6 Future Directions 135
  - References 136
  
- 7 Autophagy Eliminates Group A *Streptococcus* Invading Host Cells 139**  
*Atsuo Amano and Tamotsu Yoshimori*
  - 7.1 Group A *Streptococcus* (GAS; *Streptococcus pyogenes*) 139
  - 7.2 Adherence to Host Cells by GAS 139
  - 7.3 Invasion of Host Cells by GAS 140
  - 7.4 Survival of Intracellular Bacteria 141
  - 7.5 Streptolysin O (SLO) Enables GAS to Escape from Phagocytic/Endocytic Degradation 141
  - 7.6 Autophagy 142
  - 7.7 Intracellular GAS is Trapped by Autophagosome-like Compartments 142
  - 7.8 Atg5 is Required for Capture and Killing of GAS 144
  - 7.9 GcAVs Fuse with Lysosomes for Degradation 147
  - 7.10 Conclusion and Perspective 147
  - References 149
  
- 8 *Shigella* Invasion of Host Cells and Escape from Autophagy 151**  
*Michinaga Ogawa and Chihiro Sasakawa*
  - 8.1 *Shigella* Invasion of Epithelia 151
  - 8.2 *Shigella* Disseminate among Epithelial Cells 152
  - 8.3 *Shigella* Infection Elicits an Inflammatory Response 154
  - 8.4 *Shigella* that do not Produce IcsB Undergo Autophagic Degradation 154

8.5	<i>Shigella</i> VirG is a Target for Autophagy, but is Camouflaged by its IcsB	156
8.6	Perspective	157
	References	158
<b>9</b>	<b><i>Listeria monocytogenes</i>: A Model System for Studying Autophagy</b>	<b>161</b>
	<i>Kathryn A. Rich and Paul Webster</i>	
9.1	Listeriosis	161
9.2	Invasion of Mammalian Cells by <i>L. monocytogenes</i>	161
9.3	Autophagy	164
9.4	The Ideal Target for Studying the Early Stages of Autophagy	165
9.5	Why Other Organisms may not be as Useful to Study the Autophagic Process	167
9.6	Assembly of AVs may Result from Fusion of Cytoplasmic Membrane Structures	169
9.7	Pathogenic Cytoplasmic Bacteria can avoid the Autophagic Pathway	171
9.8	Cellular Fate of Metabolically Inhibited <i>L. monocytogenes</i>	173
	References	174
<b>10</b>	<b><i>Coxiella burnetii</i> Hijacks the Autophagy Pathway to Survive</b>	<b>179</b>
	<i>Maximiliano G. Gutierrez and María I. Colombo</i>	
10.1	Introduction	179
10.2	<i>Coxiella burnetii</i>	179
10.3	Bacterium Morphology and Phylogeny	180
10.4	Lipopolysaccharide (LPS) and Phases	180
10.5	Genome and Genetics	181
10.6	Host Response and Immunity	181
10.7	Developmental Cycle of <i>C. burnetii</i> : Small Cell Variant (SCV) and Large Cell Variant (LCV)	183
10.8	<i>C. burnetii</i> Type IV Secretion System	184
10.9	Interaction with the Endocytic and Autophagic Pathways	185
10.10	Contribution of Autophagy to RV Development	189
10.11	Autophagy and Bacterial Differentiation from SCVs to LCVs	192
10.12	Unanswered Questions and Future Perspectives	194
	Acknowledgments	195
	References	195
<b>11</b>	<b>Utilization of Endoplasmic Reticulum Membranes to Establish a Vacuole that Supports Replication of <i>Legionella pneumophila</i></b>	<b>199</b>
	<i>Mary-Pat Stein and Craig R. Roy</i>	
11.1	Introduction	199

11.2	Evidence that <i>Legionella</i> Utilizes the Autophagy Machinery for Biogenesis of a Replicative Organelle	201
11.2.1	Induction of Autophagy	201
11.2.2	Formation of Autophagosomes	202
11.2.3	Maturation of Autophagosomes and Fusion with Lysosomes	204
11.3	Evidence that the Host Autophagy Machinery is not Essential for Transport or Growth of <i>Legionella</i>	205
11.3.1	<i>Dictyostelium discoideum</i> Autophagy Mutants Support <i>Legionella</i> Growth	205
11.3.2	Morphological Differences between LCVs and Autophagosomes	205
11.3.3	Differences Between <i>Legionella</i> and Other Bacteria that Utilize Autophagy for Intracellular Survival	206
11.4	Creation of an ER-derived Vacuole that Supports <i>Legionella</i> Replication by Subversion of the Host Secretory Pathway	207
11.5	Conclusion	208
	References	209

### Part III Autophagy and Viruses

<b>12</b>	<b>Endogenous Major Histocompatibility Complex Class II Antigen Processing of Viral Antigens</b>	<b>213</b>
	<i>Dorothee Schmid and Christian Münz</i>	
12.1	Introduction	213
12.2	Classical Pathways of Antigen Processing for MHC Presentation	214
12.3	Endogenous MHC Class II Antigen Processing of Viral Antigens	215
12.4	Autophagic Delivery of Antigens for Lysosomal Degradation and MHC Class II Presentation	216
12.5	Similarities Between Sources of MHC Class II Ligands and Autophagy Substrates	218
12.6	Overlap Between the Vesicular Transport Pathways of Autophagosomes and MHC Class II Loading Compartments	219
12.7	Possible Functions of MHC Class II Presentation after Autophagy in the Immune Control of Viral Infections	220
12.8	Future Directions of Research into Endogenous MHC Class II Antigen Processing	221
12.9	Summary	222
	Acknowledgments	222
	References	222
<b>13</b>	<b>Autophagy in Antiviral Host Defense</b>	<b>227</b>
	<i>Beth Levine</i>	
13.1	Introduction	227
13.2	Role of Antiviral Signaling Pathways in Autophagy Regulation	227

13.2.1	PKR is Required for Virus-induced Autophagy	227
13.2.2	IFN- $\gamma$ Stimulates Autophagy	230
13.3	Role of Mammalian Autophagy Genes in Antiviral Host Defense	231
13.4	Role of Plant Autophagy Genes in Antiviral Host Defense	233
13.5	Evasion of Autophagy by Viruses	234
13.6	How Might Viral Evasion of Autophagy Contribute to Viral Pathogenesis?	236
13.7	Autophagy and Antigen Presentation	237
13.8	Concluding Remarks	238
	References	239

**Addendum** 242

*Jennifer Sparks and Mark R. Denison*

**Subject Index** 243

## Preface

This book was inspired by a stream of nearly simultaneous reports in 2004 and 2005 demonstrating that the fundamental biological process of autophagy, primarily known for its role in cytoplasmic maintenance, represents a previously unrecognized innate and adaptive immunity mechanism that functions as a defense against intracellular pathogens and probably has other roles within the immune system. Although hints to the role of autophagy in immune defenses and other roles in immunity have existed in the literature, the most recent burst of publications made a compelling and definitive case for the importance of autophagy in immunity. A further motivation for this project came from the opportunity to merge these new findings with the superb recent progress on genetics, biochemistry and cell biology of autophagy. The product is a book covering the basic aspects of autophagy as a cytoplasmic maintenance process playing a role in cell survival and death, its role in health and disease in general, and the new cutting edge – the role of autophagy in immunity. Using this book, the reader can find a full range of information on autophagy in one place covering both its fundamental molecular mechanisms and its many physiological roles.

Autophagy is a homeostatic intracellular mechanism, whereby a cell digests parts of its own cytoplasm for removal or turn-over, as eloquently summarized in the Foreword by P. Seglen. The term autophagy represents a set of distinct yet related pathways. These range from the robust process of macroautophagy to a rather subtle process of chaperone mediated autophagy, as detailed in Chapter 1 by J. Legakis and D. Klionsky, which also provides the fundamentals of autophagy based on the powerful genetics in yeast and other organisms. Macroautophagy sequesters significant portions of the cytosol or whole organelles into a characteristic double membrane vacuole termed the autophagosome, for eventual degradation in autolysosomes, covered extensively in Chapter 2 by S. Tooze and colleagues and Chapter 3 by N. Mizushima. Chaperone mediated autophagy, covered in some detail in Chapter 4 by A. Cuervo and colleagues and touched upon in Chapter 12 by D. Schmid and C. Münz, is a degradative pathway whereby individual proteins are imported directly into the lysosomes. In macroautophagy, or its variant manifestation of microautophagy, the trapped cytosol or organelles are eventually delivered to degradative compartments (in mammalian cells – autolysosome) for digestion and removal. In its probably

most common presentation, autophagy recycles stable cytosolic macromolecules, such as proteins with long half-lives, to supply nutrients and maintain essential cellular anabolic needs and viability under starvation conditions. The organelle removal function of autophagy is a just as important housekeeping function, by controlling the pool of peroxisomes or removing compromised mitochondria, in the latter case potentially protecting cells from unscheduled apoptosis. Although autophagy is a cell maintenance mechanism, under certain conditions, excessive autophagy can cause non-apoptotic programmed cell death, covered in Chapter 5 by Y. Debnath and C. Fung. Autophagy has been implicated in cancer, degenerative disorders, such as Huntington, Parkinson, and Alzheimer diseases, normal development, and aging, covered in detail in Chapter 4 by A. Cuervo and colleagues.

A number of very precise studies on anti-viral action of autophagy have been the true forerunner of our present more general understanding of the role of autophagy in defense against intracellular pathogens, as covered in Chapter 13 by B. Levine. More recent studies demonstrate that autophagy is also an innate immunity effector against intracellular bacteria, a central theme of the second half of this book, encompassing: Chapter 6 on *Mycobacterium tuberculosis* elimination by autophagy (Harris et al.); Chapter 7 by T. Yoshimori and A. Amano on autophagic elimination of streptococci if they invade host cells and find themselves in the cytosol; Chapter 8 on the role of autophagy in capturing the intracellular *Shigella* and its ability to escape this process; and Chapter 9 by K. Rich and P. Webster on *Listeria*. Some highly evolved pathogens have mechanisms for harnessing autophagy to their own benefit, as suggested in Chapter 10 by M. Gutierrez and M. Colombo and discussed in Chapter 11 by M.-P. Stein and C. Roy. The duality of effects of autophagy is also reflected in the Addendum to B. Levine's Chapter 13 provided by J. Sparks and M. Denison. Significantly, autophagy has a strong impact on MHCII presentation (Chapter 12 by D. Schmid and C. Münz) and is controlled by cytokines (Chapters 6 and 13) clearly extending the role of autophagy to adaptive immunity.

The goal of this volume was to provide the reader not only with the applications of autophagy in infectious diseases and immunity, but also to generate a definitive text for autophagy in general. In other words, a reader who is interested primarily in the fundamental principles and broad biological aspects of autophagy, should find this book an indispensable companion and a comprehensive source of information. For those who are primarily interested in the burgeoning field of autophagy in innate and adaptive immunity, the chapters covering the basic principles of autophagy are just as important to understand fully the underlying processes.

The book starts with a foreword by Professor Per Seglen, a doyen in the field of autophagy, who has defined many biochemical and cell biological features of autophagy and has also produced both classical and contemporary highly cited papers in this field. A careful reader of the foreword will extract many useful concepts on autophagosomes, amphisomes and autolysosomes, and precious cautionary notes on interpretations of cause and effect in diseases and in cell

survival vs. cell-death promoting faces of autophagy. The editor is indebted to Per for his willingness to write a foreword to this volume and give the reader both his sage advice on general aspects of autophagy and sum it all up including the latest developments in the context of defense against intracellular pathogens.

Furthermore, the reader is a true beneficiary of the combination of excitement and enthusiasm that pervades the field of autophagy research, and enormous expertise of the contributing authors in this area. The editor of this book is indebted immensely to all contributing authors. The chapters by Drs. Ana Maria Cuervo, Daniel Klionsky, Beth Levine, Sharon Tooze and Naboru Mizushima, taken together, can give a textbook on autophagy as a standalone product. Likewise, the chapters that link autophagy with innate and adaptive immunity by Drs. Christian Münz, Chichiro Sasakawa, Tamotsu Yoshimori, and others summarize the new breakthroughs in immunological applications of autophagy. They also define the nidus for the developing field of immunophagy, a term used by the Editor of this book in a recent review in *Current Opinion in Immunology* to describe collectively these processes.

I acknowledge the excellent coordination and open lines of communication with the publisher including the gentle prompts from Andreas Sendtko, importance of NIH funding (AI45148 and AI42999) for all my scientific activities including this one, great support and understanding at home beyond what a person can expect or deserves, and above all the collective responsiveness and enthusiasm for this book by the main protagonists in the field of autophagy. My great personal and professional respect for many of the contributors to this book has been reaffirmed in the process.

Placitas (between Albuquerque and Santa Fe), April 2006

Vojo Deretic



## Foreword

Autophagy, the mechanism by which cells envelop and degrade their own cytoplasm, plays a dual role in cellular physiology. On the one hand, autophagy serves vital functions such as the supply of essential amino acids during nitrogen starvation, the mobilization of iron from intracellular stores, the sequestration of aggregated (and potentially harmful) abnormal proteins that cannot be digested by the proteasomes, and the containment and degradation of infectious organisms. On the other hand, autophagy is frequently turned on during programmed cell death, complementing the apoptotic caspases in the orderly liquidation of the cell. In certain cases, particularly if the major caspases are somehow incapacitated, autophagy can, by itself, complete the death process. Autophagy may thus either support or prevent cell survival, depending on the biological context.

In a pathological setting, this autophagic duality may cause problems of interpretation. Many diseases are accompanied by alterations in cellular membrane fluxes, often causing massive accumulations of intracellular vacuoles of varying morphologies. Do these changes represent an attempt to combat the disease or do they contribute to disease progression (or both – or neither)? What is the nature of the vacuoles that are the affected steps in the vacuolar dynamics and in what direction are they altered?

As a first step in the analysis, the observed vacuoles need to be identified; however, unfortunately, this is not a straightforward matter. In addition to the three major types of autophagic vacuoles, i.e. autophagosomes, amphisomes and (auto)lysosomes, endosomes may contain cellular material derived from disintegrated surrounding cells or, in late, multivesicular endosomes, internalized by invagination of the endosomal delimiting membrane. In certain diseases, such as Alzheimer's, both the endocytic and autophagic pathways are afflicted, causing the accumulation of an extremely heterogeneous array of vacuoles. It should be noted that a prolonged disturbance of vacuole fluxes may induce the formation of unusual vacuoles, which may be difficult to classify by morphological criteria.

Autophagosomes, the autophagic vacuoles formed when the sequestering membrane cisternae (the phagophores) have completed the enclosure process, can be recognized in the electron microscope as areas of absolutely normal cytoplasm, circumscribed by delimiting membranes, but not deviating morpologi-

cally from their surroundings. The delimiting membrane can sometimes be seen as a double-membrane (cisternal) structure, sometimes as a thick, osmophilic layer and sometimes (artificially) as an open, electron-lucent cleft. However, since later autophagic vacuoles may contain sequestered membraneous elements closely apposed to their (single) delimiting membrane, an apparent “double membrane” is a less reliable diagnostic criterion for an autophagosome than its contents of unaltered cytoplasm.

Amphisomes, the products of fusion between endosomes and autophagosomes, quickly get their contents denatured due to acidification by the proton pump brought in by the endosomal fusion partner. The denaturation is visible in the electron microscope as a darkening and a somewhat altered morphology relative to the cytoplasmic surroundings. Multiple inputs from both autophagy and endocytosis often make the amphisomes large and complex. The contents will usually serve to distinguish amphisomes from autophagosomes, but they cannot be reliably distinguished from early autolysosomes by morphological criteria alone, particularly because the endosomal fusion partner contributes small amounts of lysosomal enzymes that may initiate degradation of the amphisomal contents. With more advanced degradation, autolysosomes usually become distinctive.

Organelle markers can make the identification of autophagic and endocytic vacuoles considerably easier. Few markers are entirely specific, but by using them in combination, information can be obtained both from the presence and the absence of a marker. In immunogold labeling studies, a relatively degradation-resistant cytosolic enzyme such as superoxide dismutase (SOD) can be used to mark autophagic vacuoles (autophagosomes, amphisomes and autolysosomes), an endocytosed, gold-conjugated protein like bovine serum albumin (BSA) can be used to mark endosomes, amphisomes and lysosomes, and a lysosomal membrane protein, e.g. LGP120, can be used to mark lysosomes. The combination of positive and negative markers will then identify endosomes ( $SOD^-/BSA^+/LGP^-$ ), autophagosomes ( $SOD^+/BSA^-/LGP^-$ ), amphisomes ( $SOD^+/BSA^+/LGP^-$ ) and autolysosomes ( $SOD^+/BSA^±/LGP^+$ ). A similar approach can be used in light microscopic studies, using, for example, the lipidated mammalian Atg8 analogue, LC3-II, as a marker for all types of autophagic vacuoles, in combination with a marker of acidic vacuoles, e.g. monodansylcadaverine and suitable endosomal and lysosomal markers.

Markers may also give information about flux perturbations. The accumulation of a specific vacuolar organelle is not necessarily the result of an increased rate of its formation, but may equally well reflect a reduced rate of its disappearance due to a defective fusion step. For example, a microtubule poison like vinblastine will block all vacuole transport and fusion, and cause autophagosomes and endosomes to accumulate. An inhibitor of intralysosomal protein degradation, like leupeptin, will not only increase the size and visibility of autolysosomes, but the impaired fusion capacity of the congested lysosomes will also cause amphisomes to pile up. Similar changes in cellular vacuole populations may occur as a result of pathological alterations in vacuolar fusion rates. Even

moderate fusion defects may have large morphological consequences if they persist over long periods of time, as may be the case in many of the slowly progressing autophagy-related diseases.

Experimental interruption of the autophagic-lysosomal flux offers useful ways of measuring flux rates. Since inhibition of intralysosomal protein degradation has been shown not to affect autophagic sequestration on a short-term basis, the intravacuolar accumulation of an autophagocytosed cytosolic enzyme after leupeptin treatment provides a precise measure of the autophagic sequestration rate (an autophagic membrane marker like LC3-II is less suitable for this purpose, because its vacuolar dynamics are influenced by factors other than the rates of sequestration and intralysosomal degradation). However, by blocking the autophagic flux altogether with a sequestration inhibitor such as 3-methyladenine (3-MA), the flux rate can be calculated, e.g. as the 3MA-sensitive part of the degradation of long-lived cellular protein. The effectiveness of this inhibitor also makes it useful in assessing the secondary effects of autophagy: if a cellular response is *insensitive* to 3-MA, an autophagic causation can be excluded. In contrast, 3-MA *sensitivity* is compatible with an involvement of autophagy, although it does not prove it (as is the case with inhibitors in general).

Although most disease-related alterations in autophagic-lysosomal traffic are likely to be secondary, they can be the primary causes of some pathological conditions, most notably the lysosomal storage diseases. In these diseases, a deficiency in a single lysosomal enzyme will cause a massive intralysosomal accumulation of undegradable material that eventually disrupts all lysosomal functions, resulting in complex cellular and pathological alterations. Autophagic and endocytic influxes to the lysosome will gradually slow down, and prelysosomal autophagic and endocytic vacuoles will accumulate, their contents of undegraded material representing a spreading of the storage syndrome beyond the lysosomes. In the closely related Danon disease, lysosomes have apparently become fusion-incompetent due to a mutation in the lysosomal membrane protein, LAMP-2, resulting in reduced influxes to the lysosome, and an accumulation of amphisomes and autophagosomes. During aging, the gradual intralysosomal accumulation of undegradable lipofuscin inclusions will similarly disturb lysosomal function and has been shown to cause a reduced chaperone-mediated lysosomal protein uptake as well as a reduced flux through the autophagic pathway.

In many neurodegenerative diseases, mutant proteins that somehow escape proteasomal degradation may instead become autophagocytosed and gradually form undegradable aggregates inside lysosomes. The resulting lysosomal storage syndrome, including the accumulation of prelysosomal autophagic vacuoles, may in the long run impair the autophagic sequestration of toxic protein aggregates and thus contribute to progression of the disease. Events that take place in the piled-up amphisomes may exacerbate the situation: in Alzheimer's disease, toxic peptides seem to be generated by intra-amphisomal proteolysis. If exocytic recycling from amphisomes takes place, it could possibly be involved in the formation of the extracellular aggregates (plaques) characteristic of several

neurodegenerative diseases. Preciously little is known about amphisome physiology; hopefully, a better understanding of this pivotal organelle, strategically located at the junction between the autophagic and endocytic pathways, may shed some light on the complex pathology of degenerative diseases.

In relation to infectious pathogens, autophagy has been shown to play a dual role. On the one hand, autophagy is a part of the innate and adaptive immune defense, participating in the generation of antigenic peptides for MHC class II presentation as well as in the sequestration, containment and degradation of bacteria like *Streptococcus*, *Shigella* and *Mycobacterium*. The bacteria fight back by attempting to suppress autophagic activity. On the other hand, bacteria like *Coxiella*, *Legionella* and several RNA viruses enter cells by a phagocytic route, but eventually become autophagocytosed intracellularly and take up residence inside autophagic vacuoles. In these cases, autophagy may promote infectivity.

Can better knowledge about autophagy help to combat autophagy-related diseases? Clearly, the slow progression of many of the degenerative diseases should leave a lot of room for therapeutic intervention. A stimulation of autophagic activity by intermittent amino acid starvation is one obvious strategy that seems to work well in mice (which can prolong their lifespan by fasting), but adequate data for humans are lacking. Autophagy-stimulatory drugs, such as rapamycin, represent another possibility that has shown considerable promise in several degenerative disease models. Conversely, in the case of infections or programmed cell death promoted by autophagy, autophagy suppressants like 3-MA have been demonstrated to be protective under experimental conditions. The development of autophagy modifiers that are pharmacologically acceptable and effective *in vivo* would seem like a promising therapeutic avenue.

Consideration should also be given to the possibility of overcoming or circumventing lysosomal dysfunctions. Some improvement has been reported with lysosomal enzyme replacement therapy to lysosomal storage disease patients, but the endocytic delivery of missing enzymes to lysosomes may be hampered by poor lysosomal uptake or fusion capacity. The amphisomes should, at least at an early stage, be more accessible. By supplying amphisomes, through the endocytic pathway, with lytic enzymes and other factors required for efficient degradation of problematic substrates, these organelles could possibly be turned into artificial lysosomes, tailored for a specific purpose. Hopefully, additional therapeutic strategies will be suggested by future research into the inner workings of the autophagic–endocytic-lysosomal network.

Oslo, December 1st, 2005

Per O. Seglen

## List of Contributors

### ***Atsuo Amano***

Department of Oral Frontier Biology  
Osaka University Graduate School  
of Dentistry  
1-8 Yamadaoka  
Suita-Osaka 565-0871  
Japan

### ***Edmond Chan***

Cancer Research UK  
London Research Institute  
44 Lincoln's Inn Fields  
London WC2A 3PX  
UK

### ***María I. Colombo***

Laboratorio de Biología Celular y  
Molecular  
Instituto de Histología y Embriología  
(IHEM)-CONICET  
Facultad de Ciencias Médicas  
Universidad Nacional de Cuyo  
Casilla de Correo 56  
5500 Mendoza  
Argentina

### ***Ana Maria Cuervo***

Department of Anatomy  
and Structural Biology  
Marion Bessin Liver Research Center  
Albert Einstein College of Medicine  
1300 Morris Park Ave  
Bronx, NY 10461  
USA

### ***Jayanta Debnath***

Department of Pathology  
and Comprehensive Cancer Center  
University of California San Francisco  
513 Parnassus Ave HSW 511  
San Francisco, CA 94143-0511  
USA

### ***Sergio De Haro***

Departments of Molecular Genetics &  
Microbiology and Cell Biology  
and Physiology  
University of New Mexico Health  
Sciences Center  
915 Camino de Salud, NE  
Albuquerque, NM 87131-001  
USA

### ***Mark R. Denison***

Department of Pediatrics  
Vanderbilt University Medical Center  
D-7235 Medical Center North  
Nashville, TN 37232-2581  
USA

***Vojo Deretic***

Departments of Molecular Genetics &  
Microbiology and Cell Biology &  
Physiology  
University of New Mexico Health  
Sciences Center  
915 Camino de Salud, NE  
Albuquerque, NM 87131-001  
USA

***Christopher Fung***

Department of Pathology  
and Comprehensive Cancer Center  
University of California San Francisco  
513 Parnassus Ave HSW 511  
San Francisco, CA 94143-0511  
USA

***Maximiliano G. Gutierrez***

Laboratorio de Biología Celular y  
Molecular  
Instituto de Histología y Embriología  
(IHEM)-CONICET  
Facultad de Ciencias Médicas  
Universidad Nacional de Cuyo  
Casilla de Correo 56  
5500 Mendoza  
Argentina

***James Harris***

Departments of Molecular Genetics &  
Microbiology and Cell Biology &  
Physiology  
University of New Mexico Health  
Sciences Center  
915 Camino de Salud, NE  
Albuquerque, NM 87131-001  
USA

***Susmita Kaushik***

Department of Anatomy  
and Structural Biology  
Marion Bessin Liver Research Center  
Albert Einstein College of Medicine  
1300 Morris Park Ave  
Bronx, NY 10461  
USA

***Daniel J. Klionsky***

Department of Molecular, Cellular  
and Developmental Biology  
University of Michigan  
210 Washtenaw Ave  
Ann Arbor, MI 48109-2216  
USA

***Robert Köchl***

Cancer Research UK  
London Research Institute  
44 Lincoln's Inn Fields  
London WC2A 3PX  
UK

***Julie E. Legakis***

Life Sciences Institute,  
Department of Molecular, Cellular  
and Developmental Biology  
University of Michigan  
210 Washtenaw Ave  
Ann Arbor, MI 48109-2216  
USA

***Beth Levine***

Department of Internal Medicine  
University of Texas Southwestern  
Medical Center  
5323 Harry Hines Blvd.  
Dallas, TX 75390-9113  
USA

**Marta Martinez-Vicente**

Department of Anatomy  
and Structural Biology  
Marion Bessin Liver Research Center  
Albert Einstein College of Medicine  
1300 Morris Park Ave  
Bronx, NY 10461  
USA

**Noboru Mizushima**

Department of Bioregulation  
and Metabolism  
Tokyo Metropolitan Institute of  
Medical Science  
3-18-22 Honkomagome, Bunkyo-ku  
Tokyo 113-8613  
Japan

**Christian Münz**

Laboratory of Viral Immunobiology  
and Christopher H. Browne Center  
for Immunology and  
Immune Diseases  
The Rockefeller University  
New York, NY 10021  
USA

**Michinaga Ogawa**

Department of Microbiology  
and Immunology  
Institute of Medical Science  
University of Tokyo  
4-6-1, Shirokanedai, Minato-ku  
Tokyo 108-8639  
Japan

**Kathryn A. Rich**

House Ear Institute  
2100 W Third Street  
Los Angeles, CA 90057  
USA

**Craig R. Roy**

Section of Microbial Pathogenesis  
Boyer Center for Molecular Medicine  
Yale University School of Medicine  
295 Congress Ave  
New Haven, CT 06536  
USA

**Chihiro Sasakawa**

Department of Microbiology  
and Immunology  
Institute of Medical Science  
University of Tokyo  
4-6-1, Shirokanedai, Minato-ku  
Tokyo 108-8639  
Japan

**Dorothee Schmid**

Laboratory of Viral Immunobiology  
and Christopher H. Browne Center  
for Immunology  
and Immune Diseases  
The Rockefeller University  
New York, NY 10021  
USA

**Jennifer Sparks**

Department of Pediatrics  
Vanderbilt University Medical Center  
D-7235 Medical Center North  
Nashville, TN 37232-2581  
USA

**Mary-Pat Stein**

Section of Microbial Pathogenesis  
Boyer Center for Molecular Medicine  
Yale University School of Medicine  
295 Congress Ave  
New Haven, CT 06536  
USA

***Sharon A. Tooze***

Cancer Research UK  
London Research Institute  
44 Lincoln's Inn Fields  
London WC2A 3PX  
UK

***Paul Webster***


House Ear Institute  
2100 W Third Street  
Los Angeles, CA 90057  
USA

***Tamotsu Yoshimori***

Department of Cell Genetics  
National Institute of Genetics  
Sokendai, Yata 1111  
Mishima, Shizuoka-ken 411-8540  
Japan




## Color Plates



**Fig. 1.1** Schematic representation of various transport routes to the lysosome/vacuole. There exist a number of pathways by which substrates are delivered to the lysosome/vacuole. Some of the sequestration events occur at the organelle membrane, these are denoted by the prefix “micro”. In other cases, the enclosure of the substrate occurs spatially away from the lysosome/vacuole membrane. These pathways begin with the prefix “macro”. Macro- and microautophagy are nonspecific degradative pathways, which include a variety of cargoes, depending on the

organism and the particular stress conditions or stage of development. Selective degradation of peroxisomes, small parts of the nucleus or foreign pathogens occurs via macropexophagy, micropexophagy, piecemeal microautophagy of the nucleus or phagocytosis, respectively. Chaperone-mediated autophagy is a receptor-driven degradative pathway that is a secondary response to starvation conditions. The biosynthetic Cvt pathway is a method of delivery for at least two vacuolar hydrolases.




**Fig. 1.2** Autophagy and the Cvt pathway. Autophagy and the Cvt pathway can be depicted as a series of separate steps. The roles of Atg and other proteins, shown to participate in different parts of the pathway, are depicted. The proteins classified by only a number are the corresponding Atg gene product. Otherwise, the protein name is specified, except for Vac8, which is indicated as “V8”. “P” denotes phosphorylation of the indicated protein. (1) *Induction*. TOR kinase becomes inactivated upon nutrient limitation, eliciting a series of events, which result in the induction of autophagy. These include partial dephosphorylation of Atg13, which alters its association with Atg1. Atg1 is thought to play a key role in the switch between growth and starvation. Autophagy-specific proteins are shown in blue, whereas Cvt-specific proteins are depicted in purple.

(2) *Cargo selection and packaging*. Examples of specific autophagy include the Cvt pathway, pexophagy and possibly mitophagy. During growth, the Cvt pathway is active. The cargo, prApe1, is synthesized as an inactive precursor and rapidly oligomerizes. Atg19, the cargo receptor, binds to the oligomer, followed by Atg11 binding to the complex. Upon induction of pexophagy, the peroxin, Pex3, is degraded, thus exposing the docking protein, Pex14. Although it is not proven, Atg11 is proposed to bind to the newly exposed Pex14. The mechanism of mitophagy is unknown. Once these binding events occur, the cargo are enveloped by a double-membrane vesicle and delivered to the lysosome/vacuole. (3) *Vesicle nucleation*. Membrane is acquired from an unknown location and the cargo associates with the forming vesicle. Membrane formation re-

quires the PI3K complex I; the components of this complex are shown in Step 3. The PI3-phosphate (PI3P) generated by this complex recruits a number of Atg proteins to the PAS, including Atg18, Atg20, Atg21, and Atg24 [24]. (4) *Vesicle expansion and completion*. There are two sets of Atg proteins, which participate in a series of ubiquitin-like (Ubl) conjugation reactions. These generate Atg12–Atg5–Atg16 and Atg8–PE (see text for details). The functions of these proteins are not known but they are needed for expansion and completion of the sequestering vesicle. (5) *Retrieval*. As most of the Atg proteins are not included in the completed vesicle, there must be a mechanism to release and return these components back to their original site. Atg9 and Atg23 have been shown to be cycling proteins, moving between the PAS and other punctate structures. Atg9 has been shown to cycle between the mitochondria

and the PAS. The non-PAS localizations of Atg23 are as yet unidentified. These two proteins may aid in the recovery of Atg components, allowing them to be reused for another round of delivery. (6) *Targeting, docking and fusion of the vesicle with the lysosome/vacuole*. The docking and fusion of the completed vesicle requires a number of components (see text for details). The fusion event results in a single-membrane vesicle within the lumen of the lysosome/vacuole. (7) *Breakdown of the vesicle and its contents*. Once inside the lysosome/vacuole, the autophagic or Cvt body must be degraded in order for the cargo to be released. The lipase responsible for vesicle lysis is thought to be Atg15. Upon release into the lumen, the cargoes of pexophagy and bulk autophagy are broken down for re-use in the cell, while the cargoes of the Cvt pathway carry out their function as hydrolases.



**Fig. 4.1** Autophagy in protein conformational disorders. Protein conformational disorders result from abnormal conformational changes in particular proteins (due to mutations or post-translational modifications) that make them prone to aggregation. In the early stages of the disorder, the abnormal proteins often block the activity of proteolytic systems normally responsible for the degradation of soluble proteins (proteasome and CMA by the lysosome), resulting in

compensatory activation of macroautophagy to eliminate the oligomeric toxic forms. As the diseases progress (late stage), a macroautophagic failure often occurs, probably due to problems in the clearance of the autophagocytosed materials, leading to the accumulation of AVs with partially degraded contents and eventually to cell death. Abbreviations: L=lysosome; LM=limiting membrane; AP=autophagosome; APL=autophagolysosome; MLB=multilamellar bodies.